

# Spotlight on CIDP:

## Evolving Perspectives on Disease and Treatment

---

Join us for a Sanofi Medical Symposium at the 2024 PNS Annual Meeting

**Sunday, 23 June 2024 | 13:00–14:00 EDT**

Room 710A, Palais des Congrès de Montréal

Lunch will be served

**sanofi**

# The evolving treatment landscape in CIDP aims to address unmet needs and reduce treatment burden to improve patients' lives.

In this Sanofi-sponsored symposium, CIDP experts will discuss the heterogeneous clinical presentation and prognosis of the disease, emphasizing unmet needs, particularly residual disability.

The experts will then explore the scientific aspects and disease pathophysiology discussing the role of demyelination and axonal damage, the use and value of biomarkers such as NfL, and potential therapeutic approaches to address residual disability in CIDP.

Concluding the session, the experts will facilitate a panel discussion on the future of CIDP treatment including the evolving perspectives on this disease, and considerations for optimizing treatment strategies.

**Join us at the 2024 PNS Annual Meeting for an exciting session.**

# Agenda

Dr. Luis Querol, MD, PhD (Chair)

*Welcome and Introduction:  
Evolution of CIDP Treatment*

13:00–13:10 PM EDT

Dr. Richard Lewis, MD

*Understanding Heterogeneity  
and Prognosis of CIDP*

13:10–13:25 PM EDT

Dr. Kathrin Doppler, MD

*Emerging Topics in CIDP  
Pathophysiology and Biomarkers*

13:25–13:35 PM EDT

All Faculty

*Panel Discussion:  
Redefining Art and Science in CIDP  
Treatment: From Now to  
the Future, and Q&A*

13:35–13:55 PM EDT

Dr. Luis Querol, MD, PhD (Chair)

Barcelona, Spain

*Meeting Close*

13:55–14:00 PM EDT





## **Dr. Luis Querol, MD, PhD (Chair)**

*Neuromuscular Diseases Unit,  
Hospital de la Santa Creu i Sant Pau,  
Barcelona, Spain*

**Dr. Luis Querol is the principal investigator of the Autoimmune Neurology group at the Neuromuscular Diseases Unit of the Hospital de la Santa Creu i Sant Pau.**

Dr. Querol received his MD from the University of Oviedo and completed his residency in neurology at the Hospital de la Santa Creu i Sant Pau in Barcelona. He pursued his PhD at the Autonomous University of Barcelona where his research focused on identifying antibodies with clinical utility in autoimmune neuropathies, notably discovering the first clinically useful marker in CIDP. During this time, he also served as an associate researcher at Yale University's Department of Neurology, where he investigated autoantibodies in multiple sclerosis and myasthenia gravis.

Dr. Querol serves as the principal investigator in the Autoimmune Neurology research group, part of ERN-NMD, at the Neuromuscular Diseases Unit of the Hospital de la Santa Creu i Sant Pau. His current laboratory and translational research activities and interests include autoimmune pathology of the peripheral nervous system, autoantibodies and immune-mediated neuropathies.



## **Dr. Richard Lewis, MD**

*Department of Neurology,  
Cedars-Sinai Medical Center,  
Los Angeles, CA, USA*

**Dr. Richard Lewis is the co-director of the Neuromuscular Clinic at Cedars-Sinai Medical Center.**

Dr. Lewis completed his neurology residency and electromyography fellowship at the University of Pennsylvania School of Medicine. He transitioned to the University of Connecticut, where he played a pivotal role in establishing the Neuromuscular Program, Electromyography Lab, and an Adult Muscular Dystrophy Clinic focusing on Amyotrophic Lateral Sclerosis (ALS). Dr. Lewis then assumed the role of Clinical Assistant Professor of Neurology at Norfolk's Eastern Virginia Medical School, where he directed a Muscular Dystrophy Association clinic.

Dr. Lewis has also held positions as Vice Chief of Neurology and Director of Clinical Neurophysiology at Harper University Hospital. At Wayne State University School of Medicine, he was Associate Clinical Chair of Neurology, directed the Hiller ALS Center, co-directed the Muscular Dystrophy Association Clinic at Detroit Medical Center, and led the Inflammatory Neuropathy Center of Excellence.

He is the Past-President of the Peripheral Nerve Society and was the Chair of the Inflammatory Neuropathy Special Interest Group (SIG). He is a co-author of both the 2021 EAN/PNS CIDP Guidelines and the 2023 GBS Guidelines.

Dr. Lewis is widely acclaimed for his groundbreaking discovery and exploration of Lewis-Sumner syndrome, a variant of chronic inflammatory demyelinating polyneuropathy (CIDP), which is a chronic disorder that requires ongoing treatment to mitigate functional decline. His research endeavors and extensive list of publications are focused on neuromuscular diseases; particularly those driven by neuroinflammation, such as CIDP and Guillain-Barré syndrome.





## **Dr. Kathrin Doppler, MD**

*Department of Neurology,  
University Hospital Würzburg,  
Würzburg, Germany*

**Dr. Kathrin Doppler is a Senior Neurologist and research group leader in the Department of Neurology at University Hospital Würzburg, Germany.**

Dr. Doppler completed her medical training at the University of Tübingen, Germany, in 2009 and then joined Claudia Sommer's research group at University Hospital Würzburg to specialize in neuromuscular disorders. She received her board certification in neurology in 2016 and has been Speaker of the Center for Neuromuscular Disorders at University Hospital Würzburg since 2021.

Her research focuses on autoimmune neuropathies, especially autoimmune nodopathies. In 2021, she joined the Board of Directors of the Inflammatory Neuropathy Consortium of the Peripheral Nerve Society.



This program is non-promotional and sponsored by Sanofi. This program was developed for scientific exchange purposes and is not eligible for continuing medical education (CME) credits. Additionally, symposium program content and the views expressed herein are those of the presenting corporate entity and not of the PNS. These programs are not an official part of the 2024 PNS Annual Meeting education or scientific programs, nor are they endorsed by the PNS. The PNS cannot affirm claims pertaining to FDA off-label medication, research use of pre-FDA drugs, or other research information that might be discussed. Symposia are industry events.

©2024 Sanofi. All rights reserved. Sanofi is a registered trademark of Sanofi or an affiliate. 450 Water Street, Cambridge, MA, USA.

MAT-GLB-2402438 v1.0 05/2024